Chilbear,

I agree with you today's release provided information that we desperately wanted; now we know the head-to-head study has not been initiated due to a lack of IRB approval. And, importantly, Cardiogenics now believes they have a package for submission to the IRB that they believe will be approved.

January will be an important month for those of us who have continued to hold our shares.

Ante